Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4133-4140

  Kelly, Jane X ^a,b   Smilkstein, Martin J ^a,b,c   Cooper, Roland A ^d   Lane, Kristin D ^d   Johnson, Robert A ^a,c   Janowsky, Aaron ^a,c   Dodean, Rozalia A ^a,b   Hinrichs, David J ^a,c   Winter, Rolf ^a,b   Riscoe, Michael ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b PORTLAND STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OLD DOMINION UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; ALKYL GROUP; AMINE; ANTIHISTAMINIC AGENT; BIOGENIC AMINE; BRIDGED COMPOUND; CHLOROQUINE; CHLORPHENIRAMINE; COCAINE; DEETHYLCHLOROQUINE; DESIPRAMINE; IMIPRAMINE; NEUROTRANSMITTER; NITROGEN; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ANTIMALARIAL ACTIVITY; ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ACRIDONES; ANIMALS; ANTIMALARIALS; CELL SURVIVAL; CELLS, CULTURED; DRUG DESIGN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; LYMPHOCYTES; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; MUTATION; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35848940753     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00669-07     Document Type: Article

References (69)

1. Ahmed, S. A., R. M. Gogal, Jr., and J. E. Walsh. 1994. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods 170:211-224.
2. American Society for Microbiology. 2007. Antimicrobial agents and chemotherapy: 2007 instructions to authors. Antimicrob. Agents Chemother. 51:1-22.
3. Baird, J. K. 2005. Effectiveness of antimalarial drugs. N. Engl. J. Med. 352:1565-1577.
4. Basco, L. K., and J. Le Bras. 1994. In vitro reversal of chloroquine resistance with chlorpheniramine against African isolates of Plasmodium falciparum. Jpn. J. Med. Sci. Biol. 47:59-63.
5. Basco, L. K., and J. Le Bras. 1990. Reversal of chloroquine resistance with desipramine in isolates of Plasmodium falciparum from Central and West Africa. Trans. R. Soc. Trop. Med. Hyg. 84:479-481.
6. Basco, L. K., P. Ringwald, and J. Le Bras. 1991. Chloroquine-potentiating action of antihistaminics in Plasmodium falciparum in vitro. Ann. Trop. Med. Parasitol. 85:223-228.
7. Bennett, T. N., A. D. Kosar, L. M. Ursos, S. Dzekunov, A. B. Singh Sidhu, D. A. Fidock, and P. D. Roepe. 2004. Drug resistance-associated PfCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH. Mol. Biochem. Parasitol. 133:99-114.
8. Bhattacharjee, A. K., D. E. Kyle, and J. L. Vennerstrom. 2001. Structural analysis of chloroquine resistance reversal by imipramine analogs. Antimicrob. Agents Chemother. 45:2655-2657.
9. Bhattacharjee, A. K., D. E. Kyle, J. L. Vennerstrom, and W. K. Milhous. 2002. A 3D QSAR pharmacophore model and quantum chemical structure-activity analysis of chloroquine (CQ)-resistance reversal. J. Chem. Inf. Comput. Sci. 42:1212-1220.
10. Bitonti, A. J., A. Sjoerdsma, P. P. McCann, D. E. Kyle, A. M. Oduola, R. N. Rossan, W. K. Milhous, and D. E. Davidson, Jr. 1988. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 242:1301-1303.
11. Boulter, M. K., P. G. Bray, R. E. Howells, and S. A. Ward. 1993. The potential of desipramine to reverse chloroquine resistance of Plasmodium falciparum is reduced by its binding to plasma protein. Trans. R. Soc. Trop. Med. Hyg. 87:303.
12. Bray, P. G., S. A. Ward, and P. M. O'Neill. 2005. Quinolines and artemisinin: chemistry, biology and history. Curr. Top. Microbiol. Immunol. 295:3-38.
13. Carosi, G., S. Caligaris, G. Fadat, F. Castelli, A. Matteelli, D. Kouka-Bemba, and G. Roscigno. 1991. Reversal of chloroquine resistance of 'wild' isolates of Plasmodium falciparum by desipramine. Trans R. Soc Trop. Med. Hyg. 85:723-724.
14. Cooper, R. A., M. T. Ferdig, X. Z. Su, L. M. Ursos, J. Mu, T. Nomura, H. Fujioka, D. A. Fidock, P. D. Roepe, and T. E. Wellems. 2002. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol. 61:35-42.
15. Cooper, R. A., C. L. Hartwig, and M. T. Ferdig. 2005. pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective. Acta Trop. 94:170-180.
16. Dzekunov, S. M., L. M. Ursos, and P. D. Roepe. 2000. Digestive vacuolar pH of intact intraerythrocytic P. falciparum either sensitive or resistant to chloroquine. Mol. Biochem. Parasitol. 110:107-124.
17. Eshleman, A. J., M. Carmolli, M. Cumbay, C. R. Martens, K. A. Neve, and A. Janowsky. 1999. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289:877-885.
18. Fidock, D. A., T. Nomura, A. K. Talley, R. A. Cooper, S. M. Dzekunov, M. T. Ferdig, L. M. Ursos, A. B. Sidhu, B. Naude, K. W. Deitsch, X. Z. Su, J. C. Wootton, P. D. Roepe, and T. E. Wellems. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861-871.
19. Fitch, C. D. 1969. Chloroquine resistance in malaria: a deficiency of chloroquine binding. Proc. Natl. Acad. Sci. USA 64:1181-1187.
20. Fivelman, Q. L., I. S. Adagu, and D. C. Warhurst. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48:4097-4102.
21. Foley, M., and L. Tilley. 1998. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79:55-87.
22. Ginsburg, H. 2005. Should chloroquine be laid to rest? Acta Trop. 96:16-23.
23. Ginsburg, H., E. Nissani, and M. Krugliak. 1989. Alkalinization of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity. Biochem. Pharmacol. 38:2645-2654.
24. Goldberg, D. E. 2005. Hemoglobin degradation. Curr. Top. Microbiol. Immunol. 295:275-291.
25. Guan, J., D. E. Kyle, L. Gerena, Q. Zhang, W. K. Milhous, and A. J. Lin. 2002. Design, synthesis, and evaluation of new chemosensitizers in multidrug-resistant Plasmodium falciparum. J. Med. Chem. 45:2741-2748.
26. Hayward, R., K. J. Saliba, and K. Kirk. 2006. The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. J. Cell Sci. 119:1016-1025.
27. Henry, M., S. Alibert, E. Orlandi-Pradines, H. Bogreau, T. Fusai, C. Rogier, J. Barbe, and B. Pradines. 2006. Chloroquine resistance reversal agents as promising antimalarial drugs. Curr. Drug Targets 7:935-948.
28. Hyde, J. E. 2002. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 4:165-174.
29. Ignatushchenko, M. V., R. W. Winter, H. P. Bachinger, D. J. Hinrichs, and M. K. Riscoe. 1997. Xanthones as antimalarial agents; studies of a possible mode of action. FEBS Lett. 409:67-73.
30. Ignatushchenko, M. V., R. W. Winter, and M. Riscoe. 2000. Xanthones as antimalarial agents: stage specificity. Am. J. Trop. Med. Hyg. 62:77-81.
31. Janowsky, A., C. Mah, R. A. Johnson, C. L. Cunningham, T. J. Phillips, J. C. Crabbe, A. J. Eshleman, and J. K. Belknap. 2001. Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice. J. Pharmacol. Exp. Ther. 298:634-643.
32. Jelinek, T., P. Schelbert, T. Loscher, and D. Eichenlaub. 1995. Quinine resistant falciparum malaria acquired in east Africa. Trop. Med. Parasitol. 46:38-40.
33. Kelly, J. X., R. Winter, M. Riscoe, and D. H. Peyton. 2001. A spectroscopic investigation of the binding interactions between 4,5-dihydroxyxanthone and heme. J. Inorg. Biochem. 86:617-625.
34. Kelly, J. X., R. Winter, D. H. Peyton, D. J. Hinrichs, and M. Riscoe. 2002. Optimization of xanthones for antimalarial activity: the 3,6-bis-omega-diethylaminoalkoxyxanthone series. Antimicrob. Agents Chemother. 46:144-150.
35. Kelly, J. X., R. W. Winter, A. Cornea, D. H. Peyton, D. J. Hinrichs, and M. Riscoe. 2002. The kinetics of uptake and accumulation of 3,6-bis-omega-diethylamino-amyloxyxanthone by the human malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 123:47-54.
36. Krogstad, D. J., P. H. Schlesinger, and I. Y. Gluzman. 1985. Antimalarials increase vesicle pH in Plasmodium falciparum. J. Cell Biol. 101:2302-2309.
37. Lakshmanan, V., P. G. Bray, D. Verdier-Pinard, D. J. Johnson, P. Horrocks, R. A. Muhle, G. E. Alakpa, R. H. Hughes, S. A. Ward, D. J. Krogstad, A. B. Sidhu, and D. A. Fidock. 2005. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24:2294-2305.
38. Laufer, M. K., P. C. Thesing, N. D. Eddington, R. Masonga, F. K. Dzinjalamala, S. L. Takala, T. E. Taylor, and C. V. Plowe. 2006. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355:1959-1966.
39. Martin, S. K., A. M. Oduola, and W. K. Milhous. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901.
40. Miki, A., K. Tanabe, T. Nakayama, C. Kiryon, and K. Ohsawa. 1992. Plasmodium chabaudi: association of reversal of chloroquine resistance with increased accumulation of chloroquine in resistant parasites. Exp. Parasitol. 74:134-142.
41. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob Chemother. 52:1.
42. Oduola, A. M., A. Sowunmi, W. K. Milhous, T. G. Brewer, D. E. Kyle, L. Gerena, R. N. Rossan, L. A. Salako, and B. G. Schuster. 1998. In vitro and in vivo reversal of chloroquine resistance in Plasmodium falciparum with promethazine. Am. J. Trop. Med. Hyg. 58:625-629.
43. Oduola, O. O., T. C. Happi, G. O. Gbotosho, O. A. Ogundahunsi, C. O. Falade, D. O. Akinboye, A. Sowunmi, and A. M. Oduola. 2004. Plasmodium berghei: efficacy and safety of combinations of chloroquine and promethazine in chloroquine resistant infections in gravid mice. Afr. J. Med. Med. Sci. 33:77-81.
44. Olliaro, P. 2001. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Ther. 89:207-219.
45. O'Neill, P. M., S. A. Ward, N. G. Berry, J. P. Jeyadevan, G. A. Biagini, E. Asadollaly, B. K. Park, and P. G. Bray. 2006. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr. Top. Med. Chem. 6:479-507.
46. Peters, W., R. Ekong, B. L. Robinson, D. C. Warhurst, and X. Q. Pan. 1990. The chemotherapy of rodent malaria. XLV. Reversal of chloroquine resistance in rodent and human Plasmodium by antihistaminic agents. Ann. Trop. Med. Parasitol. 84:541-551.
47. Price, R. N., and F. Nosten. 2001. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug Resist. Updat. 4:187-196.
48. Pukrittayakamee, S., W. Supanaranond, S. Looareesuwan, S. Vanijanonta, and N. J. White. 1994. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans. R. Soc. Trop. Med. Hyg. 88:324-327.
49. Pukrittayakamee, S., S. Wanwimolruk, K. Stepniewska, A. Jantra, S. Huyakorn, S. Looareesuwan, and N. J. White. 2003. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 47:3458-3463.
50. Riscoe, M., J. X. Kelly, and R. Winter. 2005. Xanthones as antimalarial agents: discovery, mode of action, and optimization. Curr. Med. Chem. 12:2539-2549.
51. Salama, A., and C. A. Facer. 1990. Desipramine reversal of chloroquine resistance in wild isolates of Plasmodium falciparum. Lancet 335:164-165.
52. Sangalli, B. C. 1997. Role of the central histaminergic neuronal system in the CNS toxicity of the first generation H1-antagonists. Prog. Neurobiol. 52:145-157.
53. Segurado, A. A., S. M. di Santi, and M. Shiroma. 1997. In vivo and in vitro Plasmodium falciparum resistance to chloroquine, amodiaquine and quinine in the Brazilian Amazon. Rev. Inst. Med. Trop. Sao Paulo 39:85-90.
54. Smilkstein, M., N. Sriwilaijaroen, J. X. Kelly, P. Wilairat, and M. Riscoe. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806.
55. Sowunmi, A., and A. M. Oduola. 1997. Comparative efficacy of chloroquine/chlorpheniramine combination and mefloquine for the treatment of chloroquine-resistant Plasmodium falciparum malaria in Nigerian children. Trans. R. Soc. Trop. Med. Hyg. 91:689-693.
56. Stahl, S. M. 1984. Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. J. Clin. Psychiatry 45:37-45.
57. Taylor, D., J. C. Walden, A. H. Robins, and P. J. Smith. 2000. Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing chloroquine resistance in vitro in Plasmodium falciparum. Antimicrob. Agents Chemother. 44:2689-2692.
58. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
59. van Schalkwyk, D. A., and T. J. Egan. 2006. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug. Resist. Updat. 9:211-226.
60. Waller, K. L., R. A. Muhle, L. M. Ursos, P. Horrocks, D. Verdier-Pinard, A. B. Sidhu, H. Fujioka, P. D. Roepe, and D. A. Fidock. 2003. Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J. Biol. Chem. 278:33593-33601.
61. Warhurst, D. C. 2003. Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. Malar. J. 2:31.
62. Warhurst, D. C., J. C. Craig, and I. S. Adagu. 2002. Lysosomes and drug resistance in malaria. Lancet 360:1527-1529.
63. Wellems, T. E., and C. V. Plowe. 2001. Chloroquine-resistant malaria. J. Infect. Dis. 184:770-776.
64. WHO. 2005. World malaria report 2005. WHO, Geneva, Switzerland.
65. Winter, R. W., M. Ignatushchenko, O. A. Ogundahunsi, K. A. Cornell, A. M. Oduola, D. J. Hinrichs, and M. K. Riscoe. 1997. Potentiation of an antimalarial oxidant drug. Antimicrob. Agents Chemother. 41:1449-1454.
66. Winter, R. W., J. X. Kelly, M. J. Smilkstein, R. Dodean, G. C. Bagby, R. K. Rathbun, J. I. Levin, D. Hinrichs, and M. K. Riscoe. 2006. Evaluation and lead optimization of anti-malarial acridones. Exp. Parasitol. 114:47-56.
67. Wongsrichanalai, C., A. L. Pickard, W. H. Wernsdorfer, and S. R. Meshnick. 2002. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2:209-218.
68. Yayon, A., Z. I. Cabantchik, and H. Ginsburg. 1984. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 3:2695-2700.
69. Zhi-Jun, Y., N. Sriranganathan, T. Vaught, S. K. Arastu, and S. A. Ahmed. 1997. A dye-based lymphocyte proliferation assay that permits multiple immunological analyses: mRNA, cytogenetic, apoptosis, and immunophenotyping studies. J. Immunol. Methods 210:25-39.